• About
  • Advertise
  • Privacy & Policy
  • Contact
HK Businesswire
  • Home
  • News
    • All
    • Business
    • Politics
    • PR Newswire
    • Science
    • World
    Mitrade Foundation Marks First Year with Four Community Partnerships Across Asia Pacific

    Mitrade Foundation Marks First Year with Four Community Partnerships Across Asia Pacific

    ThreatBook Named a “Strong Performer” in the Gartner® Voice of the Customer for NDR Report for the Fourth Consecutive Year

    ThreatBook Named a “Strong Performer” in the Gartner® Voice of the Customer for NDR Report for the Fourth Consecutive Year

    Eli Radiopharma Completes Series A Financing of Nearly RMB 400 Million to Advance Innovative Radiopharmaceutical Pipeline Toward Clinical Development

    Trump defends Iran war in Veterans Day address

    Nvidia preparing to oust CEO Jensen Huang: WSJ

    Pope Leo lands in Lima for Peru homecoming

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • PR Newswire
  • Business
  • World
  • Entertainment
  • Sports
  • Tech
    • All
    • Apps
    • Gadget
    • Mobile
    • Startup

    Cathay Cargo Launches AI Compliance Tool to Streamline Global Trade Operations

    PCCW Global and Druid Technology Partner on Belt and Road IoT Connectivity

    Alipay Launches Domestic Full-Stack Intelligent Agent Platform in Hangzhou

    HKT Posts 4% Profit Rise Amid Steady Local Recovery and AI-Driven Demand

    Alipay Launches AI-Powered Version ‘Abao’ to Streamline Services

    Xiaohongshu Prepares Confidential Hong Kong IPO Filing

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
  • Feature
No Result
View All Result
  • Home
  • News
    • All
    • Business
    • Politics
    • PR Newswire
    • Science
    • World
    Mitrade Foundation Marks First Year with Four Community Partnerships Across Asia Pacific

    Mitrade Foundation Marks First Year with Four Community Partnerships Across Asia Pacific

    ThreatBook Named a “Strong Performer” in the Gartner® Voice of the Customer for NDR Report for the Fourth Consecutive Year

    ThreatBook Named a “Strong Performer” in the Gartner® Voice of the Customer for NDR Report for the Fourth Consecutive Year

    Eli Radiopharma Completes Series A Financing of Nearly RMB 400 Million to Advance Innovative Radiopharmaceutical Pipeline Toward Clinical Development

    Trump defends Iran war in Veterans Day address

    Nvidia preparing to oust CEO Jensen Huang: WSJ

    Pope Leo lands in Lima for Peru homecoming

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • PR Newswire
  • Business
  • World
  • Entertainment
  • Sports
  • Tech
    • All
    • Apps
    • Gadget
    • Mobile
    • Startup

    Cathay Cargo Launches AI Compliance Tool to Streamline Global Trade Operations

    PCCW Global and Druid Technology Partner on Belt and Road IoT Connectivity

    Alipay Launches Domestic Full-Stack Intelligent Agent Platform in Hangzhou

    HKT Posts 4% Profit Rise Amid Steady Local Recovery and AI-Driven Demand

    Alipay Launches AI-Powered Version ‘Abao’ to Streamline Services

    Xiaohongshu Prepares Confidential Hong Kong IPO Filing

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
  • Feature
No Result
View All Result
HK Businesswire
No Result
View All Result
Home News PR Newswire

KOLON TISSUEGENE HIGHLIGHTS LONG-TERM SAFETY DATA AND POTENTIAL U.S. FDA PATHWAY FOR TG-C AT OARSI WORLD CONGRESS

PR Newswire by PR Newswire
28 April 2025
in PR Newswire
0
KOLON TISSUEGENE HIGHLIGHTS LONG-TERM SAFETY DATA AND POTENTIAL U.S. FDA PATHWAY FOR TG-C AT OARSI WORLD CONGRESS
0
SHARES
5
VIEWS
Share on FacebookShare on Twitter
  • THE WORLD’S MOST PRESTIGIOUS OSTEOARTHRITIS SOCIETY (OARSI) HELD FOR THE FIRST TIME IN KOREA  
  • LONG-TERM SAFETY DATA FROM OVER 1 5  YEARS SUPPORT THE SAFETY PROFILE OF TG-C, WITH PRELIMINARY SIGNS OF POTENTIAL EFFICACY BENEFITS

ROCKVILLE, Md., April 28, 2025 /PRNewswire/ — Kolon TissueGene participated in the 2025 Osteoarthritis Research Society International (OARSI) World Congress on Osteoarthritis, which took place in Songdo, South Korea, from April 24-27, 2025. This year marked the first time the globally prestigious osteoarthritis society hosted its annual congress in Korea. During the event, Kolon TissueGene presented new long-term data supporting the safety and efficacy of its investigational therapy, TG-C — the world’s first cell and gene therapy for osteoarthritis — while highlighting its potential for U.S. FDA approval.

On April 25, Kolon TissueGene delivered a presentation titled “TG-C, the First Potential DMOAD*1  Therapy: Intra-Articular Cell-Based Gene Therapy with Long-Term Safety and Insight into Delaying Total Knee Arthroplasty (TKA)”. The presentation focused on TG-C’s long-term safety profile and its potential to delay total knee arthroplasty (TKA), using long-term follow-up data (US LTS) as a basis.

The study included data from 33 subjects who participated in the U.S. Phase 2 trial and 110 subjects from the Phase 3 trial who completed two years of follow-up. The ongoing Phase 3 trial data were analyzed in a blinded manner, including both TG-C and placebo arms, allowing for an objective evaluation of the long-term safety and treatment effects.

Safety Results: No treatment-related tumor cases were reported in TG-C enrolled subjects during nearly 15 years of long-term clinical observation in the United States. Moreover, age-specific cancer incidence among TG-C subjects consistently showed lower rates compared to the general U.S. population, based on SEER (Surveillance, Epidemiology, and End Results) data from the U.S. National Cancer Institute — a compelling indicator of TG-C’s safety.

▶ Age-Specific Cancer Incidence: TG-C U.S. Long-Term Follow-Up (US LTS) vs. U.S. Average (SEER)
▶ Age-Specific Cancer Incidence: TG-C U.S. Long-Term Follow-Up (US LTS) vs. U.S. Average (SEER)

Efficacy Results: Kolon TissueGene also presented data comparing the rate and timing of knee replacement surgery among TG-C–treated subjects versus the broader osteoarthritis population*2 in the U.S. According to the Osteoarthritis Initiative (OAI), which includes 11 years of longitudinal data sponsored by the U.S. National Institutes of Health (NIH), 15.5% of 595 patients meeting TG-C–eligible criteria underwent TKA at a median of 5.1 years after osteoarthritis onset.

In contrast, only 7.0% of TG-C–treated subjects underwent TKA, with the median time to surgery extended to 5.7 years. These findings suggest that TG-C may either replace or significantly delay the need for surgical intervention — a hallmark of a disease-modifying osteoarthritis drug (DMOAD). The data supports TG-C’s potential to slow structural progression of osteoarthritis and offers a meaningful therapeutic alternative.

Executive Commentary: Dr. Moon Jong Noh, Co-CEO of Kolon TissueGene, stated, “We are honored to share meaningful TG-C data at the first-ever OARSI congress held in Korea. This opportunity reinforces our optimism for FDA approval and recognition of TG-C as the world’s first DMOAD therapy.” Co-CEO Seng Ho Jeon, who joined the company in March, added, “The scientific data presented strongly supports the safety and efficacy of TG-C. We are pursuing parallel strategies for both regulatory approval and commercialization to establish TG-C as a global blockbuster treatment.”

About OARSI: Headquartered in New Jersey, USA, the Osteoarthritis Research Society International (OARSI) is the world’s leading organization for scientists and healthcare professionals working in the field of osteoarthritis prevention and treatment. Each year, the society holds its global congress in major cities worldwide, drawing over 1,500 experts from more than 50 countries, including clinical researchers, orthopedic specialists, radiologists, and physical therapists.

About TG-C: TG-C is the world’s first cell and gene therapy developed for knee osteoarthritis and is classified as a first-in-class investigational drug. It is currently undergoing follow-up in a U.S. Phase 3 trial following completion of dosing. As of 2024, the osteoarthritis market in the seven major countries (U.S., France, Germany, Italy, Spain, U.K., and Japan) is estimated at KRW 3.8 trillion, with a projected compound annual growth rate of 5.3%, reaching KRW 5.5 trillion by 2031. The global market is expected to exceed KRW 12 trillion. Currently dominated by low-cost analgesics, the introduction of effective disease-modifying therapies like TG-C could significantly expand market potential. (Source: GlobalData, Osteoarthritis: Epidemiology Forecast to 2031, June 17, 2022)

(*1) Disease-Modifying Osteoarthritis Drug
(*2) Data from the Osteoarthritis Initiative (OAI), a large-scale, public, long-term follow-up study sponsored by the U.S. National Institutes of Health (NIH).

▶ Dr. David Hunter presenting on TG-C at the OARSI World Congress
▶ Dr. David Hunter presenting on TG-C at the OARSI World Congress

 

 

Tags: prnewswire
PR Newswire

PR Newswire

PR Newswire is the industry’s leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world.

Read More

International Travel Beckons, but Value Calls the Shots, Agoda Finds

International Travel Beckons, but Value Calls the Shots, Agoda Finds

12 November 2026
OncoRes Medical Becomes Ziva Surgical, Marking a Pivotal New Chapter in the Future of Breast Cancer Surgery

OncoRes Medical Becomes Ziva Surgical, Marking a Pivotal New Chapter in the Future of Breast Cancer Surgery

12 November 2026
  • Trending
  • Comments
  • Latest

World Winter Sports Expo 2026 Opens, Charting a New Decade for Ice and Snow and Outdoor Industries

17 October 2026
Newgen reports Revenue of ₹357 crores in Q1 FY’27, up 11% Q1 YoY; Profit After Tax at ₹63 crores, up 26% Q1 YoY

Newgen Software and the Asian Institute of Digital Finance Forge Strategic Partnership to Shape the Future of Enterprise AI

10 November 2026

Volant Aerotech Secures Firm Order from Sichuan Airlines Low Altitude for VE25-100 Passenger eVTOLs

19 October 2026

Volant Aerotech Secures Firm Order from Sichuan Airlines Low Altitude for VE25-100 Passenger eVTOLs

19 October 2026
Mitrade Foundation Marks First Year with Four Community Partnerships Across Asia Pacific

Mitrade Foundation Marks First Year with Four Community Partnerships Across Asia Pacific

12 November 2026
ThreatBook Named a “Strong Performer” in the Gartner® Voice of the Customer for NDR Report for the Fourth Consecutive Year

ThreatBook Named a “Strong Performer” in the Gartner® Voice of the Customer for NDR Report for the Fourth Consecutive Year

12 November 2026

Eli Radiopharma Completes Series A Financing of Nearly RMB 400 Million to Advance Innovative Radiopharmaceutical Pipeline Toward Clinical Development

12 November 2026

Trump defends Iran war in Veterans Day address

12 November 2026

Recent News

Mitrade Foundation Marks First Year with Four Community Partnerships Across Asia Pacific

Mitrade Foundation Marks First Year with Four Community Partnerships Across Asia Pacific

12 November 2026
ThreatBook Named a “Strong Performer” in the Gartner® Voice of the Customer for NDR Report for the Fourth Consecutive Year

ThreatBook Named a “Strong Performer” in the Gartner® Voice of the Customer for NDR Report for the Fourth Consecutive Year

12 November 2026

Eli Radiopharma Completes Series A Financing of Nearly RMB 400 Million to Advance Innovative Radiopharmaceutical Pipeline Toward Clinical Development

12 November 2026

Trump defends Iran war in Veterans Day address

12 November 2026
HK Businesswire

Stay ahead with the latest insights on Hong Kong’s economy, finance, and investments. From market trends to policy updates, we bring you in-depth analysis and expert opinions.

📩 Subscribe to our newsletter for exclusive updates.
📍 Follow us on social media for real-time news.
📧 Contact us: info@hongkong-invest.com

Follow Us

  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2025 by HKBusinesswire.com

No Result
View All Result

© 2025 by HKBusinesswire.com